Epinephrine spray formulations
AssigneeBryn Pharma, LLC
InventorsSteven Hartman, Michelle Lobel, Matthew P. Robben, Kenneth L. Dretchen, Michael Mesa
Life of this patent
Estimating the term…
Abstract
Provided herein are epinephrine spray formulations. Also provided herein are methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatment.
Claims20
A method of administering a pharmaceutical solution, comprising delivering a spray of the pharmaceutical solution from a device into a nostril of a subject in need thereof in a manner that delivers the pharmaceutical solution in a round spray plume with an ovality ratio less than about 1.4 when measured at a distance of from about 1 to about 10 cm from the device, wherein:
- (i) the device is adapted for nasal delivery;
- (ii) a volume of from about 20 μL to about 250 μL of spray is delivered;
- and
- (iii) the pharmaceutical solution comprises from about 0.5 mg to about 100 mg of epinephrine, or a pharmaceutically acceptable salt thereof.
A method of administering a pharmaceutical solution, comprising delivering a spray of the pharmaceutical solution from a device into a nostril of a subject in need thereof in a manner that delivers the pharmaceutical solution in a spray plume with a particle size distribution having a span of no more than about 2.2 when measured at a distance of from about 1 to about 10 cm from the device, wherein:
- (i) the device is adapted for nasal delivery;
- (ii) a volume of from about 20 μL to about 250 μL of spray is delivered;
- and
- (iii) the pharmaceutical solution comprises from about 0.5 mg to about 100 mg of epinephrine, or a pharmaceutically acceptable salt thereof.
A method for administering a pharmaceutical solution, comprising delivering a spray of the pharmaceutical solution from a device into a nostril of a subject in need thereof in a manner that delivers the pharmaceutical solution in a spray plume with a Dmax of less than about 28 mm when measured at a distance of from about 1 to about 10 cm from the device, wherein:
- (i) the device is adapted for nasal delivery;
- (ii) a volume of from about 20 μL to about 250 μL of spray is delivered;
- and
- (iii) the pharmaceutical solution comprises from about 0.5 mg to about 100 mg of epinephrine, or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.